Industry News
Pharmaceutical Industry News
After ending 2025 with a strong…
After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030” revenue target, outlining a roadmap to have more than 25 blockbuster medicines by the end
Paul McKenzie, Ph.D., who’s…
Paul McKenzie, Ph.D., who’s served as CSL’s chief executive and managing director for the past three years, is retiring Tuesday, with company insider Gordon Naylor set to take up the CEO post on an interim
Novo’s star-studded Wegovy pill…
Novo's star-studded Wegovy pill promotion earned the top spot among the pharma ads that played during the Super Bowl, according to TV outcomes company EDO's ranking of the ads that earned the most engagement.
Novartis CEO Vas Narasimhan saw…
Novartis CEO Vas Narasimhan saw his realized compensation swell by 30% in 2025, reaching 24.9 million Swiss francs ($32.4M) as the Swiss pharma giant exceeded its long-term financial and innovation targets.
A new campaign from Otsuka aims to…
A new campaign from Otsuka aims to educate healthcare professionals about the far-reaching impacts of attention-deficit/hyperactivity disorder on patients’ lives, beyond just the diagnostic symptoms of the condition.
Bristol Myers Squibb has signed an…
Bristol Myers Squibb has signed an agreement to partner with Evinova’s AI-native clinical development platform across the company’s global portfolio in an effort to improve efficiency and cut costs.
The agreement will see Phlow as…
The agreement will see Phlow as the first drugmaker to produce epinephrine injection API in the U.S., while Fresenius will work on formulation and finished doses to ship to U.S. hospitals and clinics, the companies
Hims & Hers caused a firestorm…
Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new oral weight loss medicine. But the reaction to the move has caused
TrumpRx: What to Know About Insurance Benefits, Pricing and Savings
People may be able to pay less for prescriptions with their insurance rather than via the new government website. The Trump drugstore is meant to help people buy medications using their own money.
As the 2026 Winter Olympics get…
As the 2026 Winter Olympics get underway in Italy this week, Eli Lilly—a partner of both Team USA and the Milan Cortina Games as a whole—is rolling out a new corporate campaign inspired by the
Biogen recorded declining sales…
Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose version of the spinal muscular atrophy treatment
NPC President and CEO John…
NPC President and CEO John O’Brien discusses the impact of policy on patient access and innovation.
The stock price of BridgeBio…
The stock price of BridgeBio plunged 15% Thursday on Pfizer's reported decision to withdraw a tafamidis patent in the EU, triggering fears of earlier generic entry in the blockbuster ATTR-CM market.
“FDA will take swift action…
“FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products,” FDA commissioner Marty Makary, M.D., said in a Feb. 5 post on X. The comments mark a
TrumpRx, the President’s Online Drugstore, Opens for Business
TrumpRx is aimed at helping patients use their own money to buy medicines. But researchers who study drug pricing warned that many patients could pay too much if they use the site.
TrumpRx Is Set to Go Live on Thursday
The government website is meant to connect Americans with drug companies to buy prescriptions directly with their own money. It is not clear how many patients will save money.
Amid the fast-moving rollout of…
Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertising’s biggest stage to help get the word out.
On this week’s “The Top Line,”…
On this week’s "The Top Line," Fierce’s Andrea Park and Gabrielle Masson dive into the most anticipated drug launches of 2026 and the blockbuster sales potential shaping biopharma’s next wave.
Amgen added to uncertainty…
Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. Roche penned a deal worth up to $1.7 billion for an RNA interference program from SanegeneBio. Daiichi Sankyo
McKesson’s Kirk Kaminsky…
McKesson’s Kirk Kaminsky discusses community oncology, trials and AI in cancer care.